文献速递前列腺癌

利用基因与基因集关联检验识别致死性前列腺癌基因

Using gene and gene-set association tests to identify lethal prostate cancer genes.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-08-17

研究采用两阶段设计,比较550例致死性前列腺癌患者与488例健康男性对照的全外显子组测序数据,通过基因及基因集罕见截短变异关联检验筛选候选基因,并在UK Biobank中验证。基因检验发现12个基因名义关联,PPP1R3A经验证与致死性前列腺癌风险显著相关(OR 2.34,CI 1.20-4.59)。

要点

  • 基因集检验显示致死性前列腺癌患者截短胚系突变负荷显著高于对照。
  • PPP1R3A在UK Biobank验证中与致死性前列腺癌风险相关(OR 2.34,CI 1.20-4.59)。
  • pGln662ArgfsTer7被确定为数据集中PPP1R3A的主要变异。

核心结论

  • 单个基因和基因集分析均识别出与致死性前列腺癌相关的候选基因。
  • PPP1R3A与致死性前列腺癌风险的新关联值得进一步研究。

研究设计与样本

  • 两阶段研究设计,第一阶段比较550例致死性前列腺癌患者与488例健康男性对照的全外显子组测序数据。
  • 通过Firth惩罚逻辑回归进行病例对照负荷检验,并通过单侧mid-p Fisher精确检验进行病例-gnomAD等位基因负荷检验。
  • 第二阶段在UK Biobank中按 ancestry 使用Firth惩罚逻辑回归评估基因,并通过meta分析合并。

主要发现

  • 基于基因的罕见变异关联检验识别出12个与致死性前列腺癌名义相关的基因。
  • 罕见变异关联检验识别出一个基因集,其截短胚系突变负荷在致死性前列腺癌患者中显著高于对照。
  • 结合基因和基因集检验结果,选择PPP1R3A、TG、PPFIBP2和BTN3A3四个名义显著基因作为候选。
  • UK Biobank验证发现PPP1R3A与致死性前列腺癌风险显著相关(比值比2.34,CI 1.20-4.59)。
  • 在本数据集的致死性前列腺癌患者中,pGln662ArgfsTer7被确定为PPP1R3A的主要变异。

关键数值与推荐

  • 基因检验识别12个名义关联基因。
  • PPP1R3A在UK Biobank验证中比值比2.34,CI 1.20-4.59。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • PPP1R3A与致死性前列腺癌风险的新关联值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent advances in the detection and treatment of prostate cancer (PCa) have reduced morbidity and mortality from this common cancer. Despite these improvements, PCa remains the second leading cause of cancer death in men in the United States. Further understanding of the genetic underpinnings of lethal PCa is required to drive risk detection and prevention and ultimately reduce mortality. We therefore set out to identify germline variants associated with cases of lethal prostate cancer (LPCa). METHODS: Using a two-stage study design, we compared whole-exome sequencing data of 550 LPCa patients to 488 healthy male controls. Men were classified as having LPCa based on medical record review. Candidate genes were identified using gene- and gene-set-based rare truncating variant association tests. Case-control burden testing through Firth's penalized logistic regression and case-gnomAD allelic burden testing through a one-sided mid-p Fisher's exact test were conducted. Each gene's p-values from these tests were combined into an omnibus p-value for candidate gene selection. In the subsequent validation stage, genes were assessed using the UK Biobank and Firth's penalized logistic regression for each ancestry, combined through meta-analysis. RESULTS: Gene-based rare variant association tests identified 12 genes nominally associated with LPCa. Rare-variant association tests identified a gene set with a significantly higher burden of truncating germline mutations in LPCa patients than controls. Combining gene- and gene-set test results, four nominally significant genes (PPP1R3A, TG, PPFIBP2, and BTN3A3) were selected as candidates. Subsequent validation using the UK Biobank found that PPP1R3A was significantly associated with LPCa risk (odds ratio 2.34, CI 1.20-4.59). Specifically, pGln662ArgfsTer7 was identified as the predominant variant in PPP1R3A among LPCa patients in our dataset. CONCLUSIONS: Both individual gene and gene-set analyses identified candidates associated with LPCa. The novel association of PPP1R3A and LPCa risk merits further investigation.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Feng BJ, Boyle JL, Wei J, et al. Using gene and gene-set association tests to identify lethal prostate cancer genes. Prostate Cancer Prostatic Dis. 2024. PMID: 39154125. doi:10.1038/s41391-024-00879-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。